roodvdb Profile Banner
Roderick van den Bergh Profile
Roderick van den Bergh

@roodvdb

Followers
854
Following
3K
Media
170
Statuses
1K

Urologist in Erasmus MC and Anser prostate cancer network, Rotterdam, Netherlands. Prostate cancer care is about the art of omission.

Utrecht, The Netherlands
Joined February 2011
Don't wanna be here? Send us removal request.
@roodvdb
Roderick van den Bergh
6 months
Targeted prostate biopsy may overestimate ISUP GG when compared to systematic biopsy, but this mainly occurs in smaller lesions. https://t.co/ljXjX1vSbG @EAU_YAUProstate @Uroweb
1
0
7
@roodvdb
Roderick van den Bergh
1 year
Thanks for inviting me to the outstanding #apcc24 in my old fellowship city #Melbourne! @phildundee @MarcDiocera @DrBenTran @DrDanielMoon @uroweb @EAU_YAUProstate @IMRASurgical
1
1
10
@roodvdb
Roderick van den Bergh
1 year
To consider when applying one-size-fits-all upfront combination therapy in M+HSPC: - Undertreated trial control arms - Mismatch age in real-life and trials - Increase CV toxicity Postpone intensification of therapy until CRPC? @AlexSherryMD @LauraBukavinaMD @UroTaji
2
3
9
@roodvdb
Roderick van den Bergh
1 year
๐Ÿšง Adding ARSI to ADT for M+ PCa gives additional risk CV-events. For which patients does the benefit of upfront combination Tx tip over to a risk and sequenced initiation at CRPC may be preferable? @BertrandTOMBAL @Silke_Gillessen @NivenMehra @dr_rajwa @DrBenTran @Ecastromarcos
1
1
11
@roodvdb
Roderick van den Bergh
1 year
Is the effect of upfront combination therapy in M+HSPC also partly due to differences in post-progression therapy? In many trials the SOC arm remains undertreated (or it is not reported). @KariTikkinen @Silke_Gillessen @LambAlastair @amerseburger https://t.co/Wd5rxkNIJs
2
8
22
@roodvdb
Roderick van den Bergh
1 year
Great to be back in ๐Ÿ‡ฏ๐Ÿ‡ต for @JUA2024 and re-unite with my 2018 JUA-EAU exchange program friend @igortsaur together with current representatives @JLVasquez82 @Filip73887202 Thanks for the honorable invite @NiigataUrology!
0
3
18
@roodvdb
Roderick van den Bergh
2 years
RCT 'PSMA-Select' ๐Ÿ‡ณ๐Ÿ‡ฑ: - Nomogram-based PLND vs - PSMA-based PLND (no PLND in PSMA neg, PLND in PSMA pos) 444 patients randomized! @declangmurphy @RannikkoAntti @stranne_johan @jpavanbasten @albert0briganti #EAU24
0
0
10
@roodvdb
Roderick van den Bergh
2 years
Improved ratio of GG1 versus GG>2 is presented in modern screening algorithms applying MRI. Still we should remain careful this may (partly) be due to stage shift caused by targeted biopsy cores. #EAU24 @SigridCarlsson @veerukasi @VickersBiostats
5
2
20
@roodvdb
Roderick van den Bergh
2 years
#GU24 New name for GG1 prostate cancer: TAFKAP (The Abnormality Formerly Known As Prostatecancer) @uroegg @urogeek @ASCO @Uroweb @AmerUrological
2
1
19
@roodvdb
Roderick van den Bergh
2 years
RCT of TP prostate biopsy without antibiotics vs TR biopsy with targeted AB: - Low overall infection rates. - Higher for TR (0% vs 1.4%). - Worse short-term (7 days) pain for TP (0.6 points on 0-10 scale). - Comparable cancer detection rates. @EAU_YAUProstate @Uroweb
0
3
15
@xiallalife
Xialla
2 years
@JGomezRivas @EAUYAUrology @GGandaglia @veerukasi @GMarra_MD @roodvdb @M_MaggiMD @dr_rajwa @EAU_YAUProstate @jo_olivier85 @Albert0Briganti @InfoAeu Since #prostatecancer is of significant interest to our audience, and since the majority of our customers have trouble deciphering medical terminology, I took the liberty of breaking it down in a blog post. Here's the link: https://t.co/Lfk86h9Gjw. I hope it's helpful to someone.
0
2
3
@EurUrolOpen
European Urology Open Science
2 years
Reliable Visualization of the Treatment Effect of Transperineal Focal Laser Ablation in Prostate Cancer Patients by Magnetic Resonance Imaging and Contrast-enhanced Ultrasound Imaging https://t.co/yhxiJplHH0 @jager_auke @hvdpoel @urohp #prostatecancer #openaccess
0
6
20
@VickersBiostats
Andrew Vickers
2 years
If patient has higher grade on MRI vs systematic biopsy, we use MRI as "true" grade, determining treatment accordingly. But even assuming MRI perfectly agrees with surgical pathology, risk is intermediate between MRI & systematic.
3
2
19
@heinvanpoppel
Hein Van Poppel
2 years
Prostate cancer does not receive the policy attention it deserves. Please share this short testimonial for the PRAISE-U project and encourage others to participate in this important initiative. Letโ€™s add Prostate Cancer to the table on menโ€™s health policy. https://t.co/is10p2wqF9
0
35
57
@roodvdb
Roderick van den Bergh
2 years
Excellent talk on prehabilitation, frailty, life expectancy, risk stratification. Important for any cancer surgeon! By @spsutkaMD #uroonco23 @GGiannarini @GPloussard @JGomezRivas @Uroweb
1
4
16
@roodvdb
Roderick van den Bergh
2 years
๐Ÿ‡ช๐Ÿ‡บ๐Ÿ‡จ๐Ÿ‡ฆCUA-EAU exchange in Montreal; a city that has so much to offer, #urology and beyond. Thanks for the amazing hospitality. @CanUrolAssoc @Uroweb @TiffanyPizioli @RSanchez_Salas @SiTanguay @vladolaru85 @NicolaMacchione @ProfCRChapple
0
2
18
@roodvdb
Roderick van den Bergh
2 years
๐Ÿ‡ช๐Ÿ‡บ๐Ÿ‡จ๐Ÿ‡ฆCUA-EAU exchange program has started in #Halifax @DalhousieU with great seaside dinner and discussions. Thank you prof Jerzy Gajewski! @NicolaMacchione @ProfCRChapple and Vlad Olaru. @Uroweb
0
1
11
@EurUrolOpen
European Urology Open Science
2 years
Current Issue: Variations in the Uptake of Active Surveillance for Prostate Cancer and Its Impact on Outcomes https://t.co/nHe6XZ8fMe #prostatecancer #UroSoMe #openscience #openaccess
1
6
5